<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPJ</journal-id>
<journal-id journal-id-type="hwp">spcpj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Pediatr (Phila)</journal-id>
<journal-title>Clinical Pediatrics</journal-title>
<issn pub-type="ppub">0009-9228</issn>
<issn pub-type="epub">1938-2707</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0009922811430346</article-id>
<article-id pub-id-type="publisher-id">10.1177_0009922811430346</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories>
<title-group>
<article-title>Interstitial Lung Disease as an Unusual Presenting Symptom in Juvenile Dermatomyositis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Dimitriades</surname><given-names>Victoria</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922811430346">1</xref>
<xref ref-type="aff" rid="aff2-0009922811430346">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gedalia</surname><given-names>Abraham</given-names></name>
<degrees>MD, FAAP, FACR</degrees>
<xref ref-type="aff" rid="aff1-0009922811430346">1</xref>
<xref ref-type="aff" rid="aff2-0009922811430346">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0009922811430346"><label>1</label>LSU Health Sciences Center, New Orleans, LA, USA</aff>
<aff id="aff2-0009922811430346"><label>2</label>Children’s Hospital of New Orleans, New Orleans, LA, USA</aff>
<author-notes>
<corresp id="corresp1-0009922811430346">Victoria Dimitriades, Children’s Hospital of New Orleans, 200 Henry Clay Avenue, New Orleans, LA 70118, USA Email: <email>varsen@lsuhsc.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>52</volume>
<issue>4</issue>
<fpage>367</fpage>
<lpage>369</lpage>
<permissions>
<copyright-statement>© The Author(s) 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<sec id="section1-0009922811430346" sec-type="intro">
<title>Introduction</title>
<p>Juvenile dermatomyositis is a multisystem disease primarily manifested by nonsuppurative inflammation of the striated muscle, skin, and connective tissues. Patients often present with symmetrical proximal muscle weakness, a characteristic heliotropic discoloration of the eyelids, and papules over the extensor surfaces of the joints, known as <italic>Gottron’s papules</italic>.<sup><xref ref-type="bibr" rid="bibr1-0009922811430346">1</xref></sup> Additionally, there is often calcinosis of the subcutaneous tissues. Although this disease tends to target the skin and musculature, other organ systems may also have sequelae of this vasculitis, including the cardiovascular, pulmonary, and gastrointestinal systems.</p>
</sec>
<sec id="section2-0009922811430346" sec-type="cases">
<title>Case Report</title>
<p>A 13-year-old, previously healthy male, was seen as an outpatient by the gastroenterology service for a recent history of intermittent abdominal pain and weight loss. Abdominal computed tomographic (CT) scan showed no pathology in the abdomen, but ground glass opacities were noted in the lung bases, which prompted immunologic and infectious disease evaluations. A dedicated lung CT showed patchy ground glass opacifications in the periphery of the lung with central sparing and no adenopathy or fluid (<xref ref-type="fig" rid="fig1-0009922811430346">Figure 1</xref>). The patient denied cough, shortness of breath, fatigue or fever. Immune work-up revealed normal complete blood count, immunoglobulins, and lymphocyte subpopulations. Infectious disease evaluation, including testing for HIV, tuberculosis, Epstein–Barr virus, cytomegalovirus, hepatitis B, and stool culture for parasites, was also negative. The patient developed a new onset chest pain and mild shortness of breath and examination revealed remarkable subcutaneous crepitus on both sides of neck. Radiographic evaluation confirmed a pneumomediastinum. After resolution, a bonchoalveolar lavage revealed many lymphocytes and histiocytes, but bacterial, viral, and fungal cultures were negative. Hypersensitivity pneumonitis panel and parasitic antibody panel were also negative. Approximately 2 months after the initial evaluation, the patient presented for ongoing follow-up with a 1-week history of new-onset facial and extremity rash with progressive muscle weakness and fatigue. On examination, he was found to have a heliotropic rash with significant proximal muscle weakness. On admission, antinuclear antibody and full antibody profile testing, including RNP, Sm, SSA, SSB, SCL-70, and Jo-1 antibody, were negative with negative ANCA testing and ACE level as well. Aldolase was within normal limits at 8.6 U/L (&lt;9.7), but creatine kinase was mildly elevated at 304 U/L (normal = 55-170 U/L). Magnetic resonance imaging of the thighs showed increased signal scattered throughout, and muscle biopsy confirmed perfascicular atrophy, degenerating/regenerating muscle fibers, and lymphocytic muscle infiltration with immunofluorescence to both IgG and complement. Lung biopsy taken during the same procedure showed diffuse interstitial fibrosis and lymphocytic infiltrate consistent with a pattern of usual interstitial pneumonia (<xref ref-type="fig" rid="fig2-0009922811430346">Figure 2</xref>). The patient was given a diagnosis of juvenile dermatomyositis with interstitial lung disease (ILD). After bone marrow biopsy was found to be normocellular, the patient was started on prednisone at 2 mg/kg/d with rapid resolution of both the rash and the muscular weakness within several days. Over time, hydroxychloroquine was also started as a steroid sparing agent and the prednisone has gradually been tapered with good tolerance. Currently, he is on a very lose dose and is clinically stable. Pulmonary function testing, which initially showed significant obstructive lung disease and limited diffusion capacity, has returned to near-normal numbers. Both CPK and aldolase have remained within normal limits. Physical and Occupational therapy has been ongoing and the patient reports feeling well with no cough or shortness of breath and a regained ability to play sports.</p>
<fig id="fig1-0009922811430346" position="float">
<label>Figure 1.</label>
<caption>
<p>Lung computed tomographic scan showing peripheral air space opacities with central sparing, noted more significantly at the lung bases</p>
</caption>
<graphic xlink:href="10.1177_0009922811430346-fig1.tif"/></fig>
<fig id="fig2-0009922811430346" position="float">
<label>Figure 2.</label>
<caption>
<p>Lung tissue with fibrosis and lymphocytic infiltrate consistent with a pattern of usual interstitial pneumonia</p>
<p>Histopathology photo courtesy of Dr Randall Craver, Children’s Hospital, New Orleans.</p>
</caption>
<graphic xlink:href="10.1177_0009922811430346-fig2.tif"/></fig>
</sec>
<sec id="section3-0009922811430346" sec-type="discussion">
<title>Discussion</title>
<p>Interstitial lung disease is a rarely reported complication of juvenile dermatomyositis,<sup><xref ref-type="bibr" rid="bibr2-0009922811430346">2</xref>,<xref ref-type="bibr" rid="bibr3-0009922811430346">3</xref></sup> and pneumomediastinum related to this is even less so.<sup><xref ref-type="bibr" rid="bibr4-0009922811430346">4</xref>,<xref ref-type="bibr" rid="bibr5-0009922811430346">5</xref></sup> However, recent reports indicate that lung disease can be seen in up to 80% of patients with JDM and, though often asymptomatic, it is most often associated with a reduction in ventilatory capacity.<sup><xref ref-type="bibr" rid="bibr6-0009922811430346">6</xref>,<xref ref-type="bibr" rid="bibr7-0009922811430346">7</xref></sup> When associated with decreased diffusion capacity, the prognosis can be poor. The etiology of ILD is thought to be related to an influx of Th1 cells and cytokines into the lung environment, which promote inflammation and eventually fibrosis.<sup><xref ref-type="bibr" rid="bibr8-0009922811430346">8</xref></sup></p>
<p>In patients with ILD and pneumomediastinum, corticosteroids and immunosuppressants are advocated early in disease course to decrease the risk of mortality and to improve lung function.<sup><xref ref-type="bibr" rid="bibr9-0009922811430346">9</xref></sup> Corticosteroids remain the first step in early treatment, at doses of 1 to 2 mg/kg/d. In an effort to decrease the treatment-related side effects, or if response to steroids is slow, steroid sparing agents should also be initiated aggressively. Agents that have been used include cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporine, and rituximab.<sup><xref ref-type="bibr" rid="bibr10-0009922811430346">10</xref></sup></p>
<p>In our patient, ILD was the presenting symptom of his juvenile dermatomyositis and may not have been discovered until well after his rash and myopathy had become clinically apparent. In this case, early detection of our patient’s ILD has allowed for more consistent pulmonary monitoring and treatment.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict"><label>Declaration of Conflicting Interests</label><p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn>
<fn fn-type="financial-disclosure"><label>Funding</label><p>The authors received no financial support for the research, authorship, and/or publication of this article.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0009922811430346">
<label>1.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Rider</surname><given-names>RG</given-names></name>
<name><surname>Lindsley</surname><given-names>CB</given-names></name>
<name><surname>Cassidy</surname><given-names>JT</given-names></name>
</person-group>. <article-title>Juvenile dermatomyositis</article-title>. In: <person-group person-group-type="editor">
<name><surname>Cassidy</surname><given-names>JT</given-names></name>
<name><surname>Petty</surname><given-names>RE</given-names></name>
<name><surname>Laxer</surname><given-names>RM</given-names></name>
<name><surname>Lindsley</surname><given-names>CB</given-names></name>
</person-group>, eds. <source>Textbook of Pediatric Rheumatology</source>. <edition>6th ed.</edition> <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Saunders Elsevier</publisher-name>; <volume>2011</volume>:<fpage>375</fpage>-<lpage>413</lpage>.</citation>
</ref>
<ref id="bibr2-0009922811430346">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marie</surname><given-names>I</given-names></name>
<name><surname>Hachulla</surname><given-names>E</given-names></name>
<name><surname>Chérin</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Interstitial lung disease in polymyositis and dermatomyositis</article-title>. <source>Arthritis Rheum</source>. <year>2002</year>;<volume>47</volume>:<fpage>614</fpage>-<lpage>622</lpage>.</citation>
</ref>
<ref id="bibr3-0009922811430346">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fathi</surname><given-names>M</given-names></name>
<name><surname>Lundberg</surname><given-names>IE</given-names></name>
</person-group>. <article-title>Interstitial lung disease in polymyositis and dermatomyositis</article-title>. <source>Curr Opin Rheum</source>. <year>2005</year>;<volume>17</volume>:<fpage>701</fpage>-<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr4-0009922811430346">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Al-Mayouf</surname><given-names>SM</given-names></name>
<name><surname>Al-Eid</surname><given-names>W</given-names></name>
<name><surname>Bahabri</surname><given-names>S</given-names></name>
<name><surname>Al-Mofada</surname><given-names>S</given-names></name>
</person-group>. <article-title>Interstitial pneumonitis and air leakage in juvenile dermatomyositis</article-title>. <source>Rheumatology (Oxford)</source>. <year>2001</year>;<volume>40</volume>:<fpage>588</fpage>-<lpage>590</lpage>.</citation>
</ref>
<ref id="bibr5-0009922811430346">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Le Goff</surname><given-names>B</given-names></name>
<name><surname>Chérin</surname><given-names>P</given-names></name>
<name><surname>Cantagrel</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis</article-title>. <source>Arthritis Rheum</source>. <year>2009</year>;<volume>61</volume>:<fpage>108</fpage>-<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr6-0009922811430346">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanner</surname><given-names>H</given-names></name>
<name><surname>Aaløkken</surname><given-names>TM</given-names></name>
<name><surname>Gran</surname><given-names>JT</given-names></name>
<name><surname>Sjaastad</surname><given-names>I</given-names></name>
<name><surname>Johansen</surname><given-names>B</given-names></name>
<name><surname>Flatø</surname><given-names>B</given-names></name>
</person-group>. <article-title>Pulmonary outcome in juvenile dermatomyositis: a case-control study</article-title>. <source>Ann Rheum Dis</source>. <year>2011</year>;<volume>70</volume>:<fpage>86</fpage>-<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr7-0009922811430346">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trapani</surname><given-names>S</given-names></name>
<name><surname>Camiciottoli</surname><given-names>G</given-names></name>
<name><surname>Vierucci</surname><given-names>A</given-names></name>
<name><surname>Pistolesi</surname><given-names>M</given-names></name>
<name><surname>Falcini</surname><given-names>F</given-names></name>
</person-group>. <article-title>Pulmonary involvement in juvenile dermatomyositis: a two-year longitudinal study</article-title>. <source>Rheumatology (Oxford)</source>. <year>2001</year>;<volume>40</volume>:<fpage>216</fpage>-<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr8-0009922811430346">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurasawa</surname><given-names>K</given-names></name>
<name><surname>Nawata</surname><given-names>Y</given-names></name>
<name><surname>Takabayashi</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis</article-title>. <source>Clin Exp Immunol</source>. <year>2002</year>;<volume>129</volume>:<fpage>541</fpage>-<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr9-0009922811430346">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saketkoo</surname><given-names>LA</given-names></name>
<name><surname>Ascherman</surname><given-names>DP</given-names></name>
<name><surname>Cottin</surname><given-names>V</given-names></name>
<name><surname>Christopher-Stine</surname><given-names>L</given-names></name>
<name><surname>Danoff</surname><given-names>SK</given-names></name>
<name><surname>Oddis</surname><given-names>CV</given-names></name>
</person-group>. <article-title>Interstitial lung disease in idiopathic inflammatory myopathy</article-title>. <source>Curr Rheumatol Rev</source>. <year>2010</year>;<volume>6</volume>:<fpage>108</fpage>-<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr10-0009922811430346">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>I</given-names></name>
<name><surname>Yamada</surname><given-names>M</given-names></name>
<name><surname>Takahashi</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A</article-title>. <source>Rheumatology (Oxford)</source>. <year>2003</year>;<volume>43</volume>:<fpage>371</fpage>-<lpage>374</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>